# US 2024/0198131 A1 · Uv a light exposure increases mitochondrial anti-viral protein expression in tracheal cells via cell-to-cell communication and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0198131 A1
- Document ID: US20240198131A1
- Status: Published application
- Kind: A1
- Application number: 18/288,146
- Filed: 2022-05-05
- Published: 2024-06-20
- Earliest claimed: 2021-05-05
- Assignees: Cedars-Sinai Medical Center
- Applicants: Cedars-Sinai Medical Center
- Inventors: Mark Pimentel; Ali Rezaie; Gabriela Guimaraes Sousa Leite; Ruchi Mathur; Gil Y. Melmed
- Web page: https://patentgrep.com/patent/US20240198131A1

## CPC

- A61N 5/0601: {Apparatus for use inside the body}
- A61N 5/0624: {for eliminating microbes, germs, bacteria on or in the body}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61N 2005/0604: {Lungs and/or airways}
- A61N 2005/0606: {Mouth}
- A61N 2005/0607: {Nose}
- A61N 2005/0608: {Rectum}
- A61N 2005/061: {Bladder and/or urethra}
- A61N 2005/0611: {Vagina}
- A61N 2005/0651: {Diodes}
- A61N 2005/0661: {ultraviolet}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Mitochondrial antiviral signaling (MA VS) protein mediates innate antiviral responses, and is an important component of the response to severe acute respiratory syndrome coronavirus-2 (SARS-COV-2). Herein methods are provided to increase expression of mitochondrial antiviral signaling (MAVS) protein in epithelial cells by use of a UVA therapy to expose the epithelial cells to the UVA therapy, or to contact a first set of epithelial cells with a second set of epithelial cells which have been exposed to the UVA therapy, or to contact a first set of epithelial cells with the cell lysates of the second set of epithelial cells that have been exposed to the UVA therapy.

## Claims

### Claim 1

A method of increasing expression of mitochondrial antiviral signaling (MAVS) protein in epithelial cells in a subject in need thereof, comprising:
exposing epithelial cells to an effective amount of ultraviolet A (UVA), so as to increase expression of MAVS protein in the epithelial cells or in distant epithelial cells unexposed to the effective amount of UVA, wherein the increased expression of MAVS protein is compared to not having been exposed to the effective amount of the UVA or compared to a control.

### Claim 2 (depends on 1)

The method of claim 1, wherein the epithelial cells comprise tracheal epithelial cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein the epithelial cells comprise ciliated epithelial cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein the epithelial cells comprise ciliated tracheal epithelial cells.

### Claim 5 (depends on 1)

The method of claim 1, wherein the epithelial cells comprise human nasal epithelial cells, human trachea epithelial cells, or both.

### Claim 6 (depends on 1)

The method of claim 1, wherein the epithelial cells comprise human lung epithelial cells.

### Claim 7 (depends on 1)

The method of claim 1, wherein exposing epithelial cells to an effective amount of UVA comprises exposing nasal epithelial cells, oral epithelial cells, olfactory epithelial cells, or combinations thereof to the effective amount of UVA.

### Claim 8 (depends on 7)

The method of claim 7, wherein exposing nasal epithelial cells, oral epithelial cells, olfactory epithelial cells, or combinations thereof increases MAVS protein expression in epithelial cells in the subject's trachea, bronchi, or both.

### Claim 9 (depends on 7)

The method of claim 7, wherein exposing nasal epithelial cells, olfactory epithelial cells, oral epithelial cells, or combinations thereof increases MAVS protein expression in epithelial cells in the subject's lung.

### Claim 10 (depends on 1)

The method of claim 1, wherein exposing epithelial cells to an effective amount of UVA comprises exposing urethral epithelial cells, bladder epithelial cells, vaginal epithelial cells, urogenital epithelial cells, rectal epithelial cells, gastrointestinal epithelial cells other than rectal epithelial cells, outer ear epithelial cells, middle ear epithelial cells, or combinations thereof to an effective amount of UVA.

### Claim 11 (depends on 10)

The method of claim 10, wherein
exposing urethral epithelial cells increases MAVS protein expression in epithelial cells in the subject's bladder,
exposing vaginal epithelial cells increases MAVS protein expression in epithelial cells in the subject's uterus,
exposing urogenital epithelial cells increases MAVS protein expression in epithelial cells in the subject's urethra or bladder,
exposing rectal epithelial cells increases MAVS protein expression in epithelial cells in the subject's rectum or colon,
exposing gastrointestinal epithelial cells other than rectal epithelial cells increases MAVS protein expression in epithelial cells in the subject's gastrointestinal tract,
exposing outer ear epithelial cells increases MAVS protein expression in epithelial cells in the subject's middle or inner ear,
exposing middle ear epithelial cells increases MAVS protein expression in epithelial cells in the subject's inner ear, or
combinations thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject exhibits one or more symptoms of a microbial infection for no more than 3 days, 3-5 days, 5-7 days, or 7-10 days.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein the subject is not administered general anesthesia, regional anesthesia, local anesthesia, twilight anesthesia, or a sedative.

### Claim 17 (depends on 1)

The method of claim 1, further comprising selecting the subject who exhibits one or more symptoms of a microbial infection as the subject in need thereof before exposing epithelial cells to an effective amount of UVA; wherein the microbial infection is a viral infection, bacterial infection, or fungal infection.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The method of claim 1, wherein the effective amount of the UVA comprises 5 milliWatt/cm2 (mW/cm2) or more for a duration of 1 minute or more, or wherein the effective amount of the UVA comprises a UVA intensity of 5 mW/cm2 or more.

### Claim 20 (depends on 1)

The method of claim 1, wherein the effective amount of the UVA comprises 2-5 mW/cm2 for a duration of at least 20 minute, or wherein the effective amount of the UVA comprises a UVA intensity of 2-5 mW/cm2.

### Claim 21 (depends on 1)

The method of claim 1, wherein the exposure to the effective amount of the UVA comprises exposing for a first period of time, followed by exposing for a subsequent period of time.

### Claim 22 (depends on 1)

The method of claim 1, wherein the control is a reference value of the epithelial cells before exposure to the UVA, epithelial cells before contact with a pathogen, or population of epithelial cells not exposed to the amount of the UVA and not infected with a pathogen.

### Claim 23

A method of assessing ultraviolet A (UVA) treatment in a subject in need thereof comprising:
assaying a biological sample obtained from a subject having been exposed to UVA treatment for mitochondrial antiviral signaling (MAVS) protein expression level,
wherein MAVS protein expression level higher than the subject's baseline level or higher than a control level indicates the treatment being effective.

### Claim 24

A method of administering ultraviolet A (UVA) treatment in a subject in need thereof, comprising:
assaying mitochondrial antiviral signaling (MAVS) protein expression in a biological sample obtained from a subject having been exposed to UVA treatment; and
continuing to administer UVA treatment to the subject if MAVS protein expression is lower compared to the subject's baseline level, or compared to a control, or relative to a target level.

### Claim 25 (depends on 1)

A method of administering ultraviolet A (UVA) treatment in a subject in need thereof, comprising:
performing the method of claim 1, in a subject having a low mitochondrial antiviral signaling (MAVS) protein expression as compared to a control, which is indicative of the subject needing the UVA treatment;
or
performing the method of claim 1, in a subject having a MAVS protein expression higher than the subject's baseline level, or compared to a control, which is indicative of the UVA treatment being effective.
